Publications

Authors:

Dinoto, Alessandro; Gastaldi, Matteo; Iorio, Raffaele; Marini, Sofia; Damato, Valentina; Farina, Antonio; Zoccarato, Marco; Sechi, Elia; Pinna, Francesca; Maniscalco, Giorgia Teresa; Barnabei, Ruggero; Zuliani, Luigi; Ferrari, Sergio; Mariotto, Sara

Title:

Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders

Year:

2022

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

Elettronico

Referee:

Sì

Name of journal:

MULTIPLE SCLEROSIS AND RELATED DISORDERS

ISSN of journal:

2211-0348

N° Volume:

63

Number or Folder:

103827

Page numbers:

1-4

Keyword:

Autoimmune encephalitis; CNS autoantibodies; SARS-CoV-2; Safety; Vaccination

Short description of contents:

Objectives: In this retrospective multicenter study, we evaluated the safety of SARS-CoV-2 vaccination in patients harboring autoantibodies targeting neuronal surface and/or synaptic antigens. Methods: From eight Italian Neurology Units, we included patients with: a) serum and/or CSF positivity for specific neuronal autoantibodies; b) a compatible neurological syndrome; and c) available follow-up ≥6 weeks after vaccination with any of the approved SARS-CoV-2 vaccines. Demographics, clinical data, and information regarding previous SARS-CoV-2 infection and vaccination were collected. Disease relapses were considered "post-infectious" or "post-vaccination" when occurring within 6 weeks from infection/vaccination. Results: We included 66 patients; 7/66 (11%) had a previous history of SARS-CoV-2 infection and 1/7 (14%) had post-infection relapses. BNT162b2-Pfizer-BioNTec was administered in 55 cases (83.3%) and mRNA-1273-Moderna in 11 (16.7%). The median number of doses administered per patient was 2 (1-3) and >50% of patients did not experience side effects. Five patients (8%) had post-vaccination relapses (seizure 3/5); 4/5 improved after immunotherapy, while one did not receive immunotherapy and worsened. Patients with post-vaccination relapses had higher disability scores at vaccination (p = 0.025), a trend favoring Leucine-rich glioma-inactivated protein 1 LGI1 glutamic acid decarboxylase 65 (GAD65) antibodies (p =  0.054) and shorter time from last relapse (p = 0.057). Discussion: Our data support the safety of SARS-CoV-2 vaccines in patients with neurological disorders associated with antibodies to neuronal and synaptic antigens.

Web page:

https://doi.org/10.1016/j.msard.2022.103827

Product ID:

126294

Handle IRIS:

11562/1063850

Last Modified:

November 15, 2022

Bibliographic citation:

Dinoto, Alessandro; Gastaldi, Matteo; Iorio, Raffaele; Marini, Sofia; Damato, Valentina; Farina, Antonio; Zoccarato, Marco; Sechi, Elia; Pinna, Francesca; Maniscalco, Giorgia Teresa; Barnabei, Ruggero; Zuliani, Luigi; Ferrari, Sergio; Mariotto, Sara, Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders «MULTIPLE SCLEROSIS AND RELATED DISORDERS» , vol. 63 , n. 103827 , 2022 , pp. 1-4

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo